These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 28370449)

  • 1. The role of high-field magnetic resonance imaging in parkinsonian disorders: Pushing the boundaries forward.
    Lehericy S; Vaillancourt DE; Seppi K; Monchi O; Rektorova I; Antonini A; McKeown MJ; Masellis M; Berg D; Rowe JB; Lewis SJG; Williams-Gray CH; Tessitore A; Siebner HR;
    Mov Disord; 2017 Apr; 32(4):510-525. PubMed ID: 28370449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imaging the Substantia Nigra in Parkinson Disease and Other Parkinsonian Syndromes.
    Bae YJ; Kim JM; Sohn CH; Choi JH; Choi BS; Song YS; Nam Y; Cho SJ; Jeon B; Kim JH
    Radiology; 2021 Aug; 300(2):260-278. PubMed ID: 34100679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Longitudinal Changes in Neuromelanin MRI Signal in Parkinson's Disease: A Progression Marker.
    Gaurav R; Yahia-Cherif L; Pyatigorskaya N; Mangone G; Biondetti E; Valabrègue R; Ewenczyk C; Hutchison RM; Cedarbaum JM; Corvol JC; Vidailhet M; Lehéricy S
    Mov Disord; 2021 Jul; 36(7):1592-1602. PubMed ID: 33751655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuroimaging Advances in Parkinson's Disease and Atypical Parkinsonian Syndromes.
    Saeed U; Lang AE; Masellis M
    Front Neurol; 2020; 11():572976. PubMed ID: 33178113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Parkinson's disease-related increase of T2*-weighted hypointensity in substantia nigra pars compacta.
    Langley J; Huddleston DE; Sedlacik J; Boelmans K; Hu XP
    Mov Disord; 2017 Mar; 32(3):441-449. PubMed ID: 28004859
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative MRI markers in Parkinson's disease and parkinsonian syndromes.
    Arribarat G; Péran P
    Curr Opin Neurol; 2020 Apr; 33(2):222-229. PubMed ID: 32049737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuromelanin-MRI to Quantify and Track Nigral Depigmentation in Parkinson's Disease: A Multicenter Longitudinal Study Using Template-Based Standardized Analysis.
    Xing Y; Sapuan AH; Martín-Bastida A; Naidu S; Tench C; Evans J; Sare G; Schwarz ST; Al-Bachari S; Parkes LM; Kanavou S; Raw J; Silverdale M; Bajaj N; Pavese N; Burn D; Piccini P; Grosset DG; Auer DP
    Mov Disord; 2022 May; 37(5):1028-1039. PubMed ID: 35165920
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The utility of the combined use of
    Matsusue E; Fujihara Y; Tanaka K; Aozasa Y; Shimoda M; Nakayasu H; Nakamura K; Ogawa T
    Acta Radiol; 2019 Feb; 60(2):230-238. PubMed ID: 29804474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MRI-based neuroimaging: atypical parkinsonisms and other movement disorders.
    Kassubek J
    Curr Opin Neurol; 2018 Aug; 31(4):425-430. PubMed ID: 29952835
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Longitudinal Progression Markers of Parkinson's Disease: Current View on Structural Imaging.
    Yang J; Burciu RG; Vaillancourt DE
    Curr Neurol Neurosci Rep; 2018 Oct; 18(12):83. PubMed ID: 30280267
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuromelanin in parkinsonian disorders: an update.
    Martin-Bastida A; Pietracupa S; Piccini P
    Int J Neurosci; 2017 Dec; 127(12):1116-1123. PubMed ID: 28460588
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Update on diffusion MRI in Parkinson's disease and atypical parkinsonism.
    Meijer FJ; Bloem BR; Mahlknecht P; Seppi K; Goraj B
    J Neurol Sci; 2013 Sep; 332(1-2):21-9. PubMed ID: 23866820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MRI for the differential diagnosis of neurodegenerative parkinsonism in clinical practice.
    Seppi K
    Parkinsonism Relat Disord; 2007; 13 Suppl 3():S400-5. PubMed ID: 18267272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protocol of a single group prospective observational study on the diagnostic value of 3T susceptibility weighted MRI of nigrosome-1 in patients with parkinsonian symptoms: the N3
    Schwarz ST; Xing Y; Naidu S; Birchall J; Skelly R; Perkins A; Evans J; Sare G; Martin-Bastida A; Bajaj N; Gowland P; Piccini P; Auer DP
    BMJ Open; 2017 Dec; 7(12):e016904. PubMed ID: 29247084
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Substantia nigra neuromelanin-MR imaging differentiates essential tremor from Parkinson's disease.
    Reimão S; Pita Lobo P; Neutel D; Guedes LC; Coelho M; Rosa MM; Azevedo P; Ferreira J; Abreu D; Gonçalves N; Nunes RG; Campos J; Ferreira JJ
    Mov Disord; 2015 Jun; 30(7):953-9. PubMed ID: 25758364
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuromelanin MRI is useful for monitoring motor complications in Parkinson's and PARK2 disease.
    Hatano T; Okuzumi A; Kamagata K; Daida K; Taniguchi D; Hori M; Yoshino H; Aoki S; Hattori N
    J Neural Transm (Vienna); 2017 Apr; 124(4):407-415. PubMed ID: 28160151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imaging of Substantia Nigra in Parkinson's Disease: A Narrative Review.
    Feraco P; Gagliardo C; La Tona G; Bruno E; D'angelo C; Marrale M; Del Poggio A; Malaguti MC; Geraci L; Baschi R; Petralia B; Midiri M; Monastero R
    Brain Sci; 2021 Jun; 11(6):. PubMed ID: 34207681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Susceptibility MRI captures nigral pathology in patients with parkinsonian syndromes.
    Lewis MM; Du G; Baccon J; Snyder AM; Murie B; Cooper F; Stetter C; Kong L; Sica C; Mailman RB; Connor JR; Huang X
    Mov Disord; 2018 Sep; 33(9):1432-1439. PubMed ID: 29756231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diffusion tensor imaging of the substantia nigra in Parkinson's disease revisited.
    Langley J; Huddleston DE; Merritt M; Chen X; McMurray R; Silver M; Factor SA; Hu X
    Hum Brain Mapp; 2016 Jul; 37(7):2547-56. PubMed ID: 27029026
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Morphological MRI investigations of the hypothalamus in 232 individuals with Parkinson's disease.
    Gorges M; Kuntz B; Del Tredici K; Schmidt DG; Müller HP; Ludolph AC; Dupuis L; Kassubek J
    Mov Disord; 2019 Oct; 34(10):1566-1570. PubMed ID: 31433875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.